254 related articles for article (PubMed ID: 22378189)
1. Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
Kwek SS; Cha E; Fong L
Nat Rev Cancer; 2012 Mar; 12(4):289-97. PubMed ID: 22378189
[TBL] [Abstract][Full Text] [Related]
2. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
3. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.
Kwek SS; Dao V; Roy R; Hou Y; Alajajian D; Simko JP; Small EJ; Fong L
J Immunol; 2012 Oct; 189(7):3759-66. PubMed ID: 22956585
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.
Youlin K; Li Z; Xiaodong W; Xiuheng L; Hengchen Z
Clin Dev Immunol; 2012; 2012():439235. PubMed ID: 22312406
[TBL] [Abstract][Full Text] [Related]
5. Future directions in tumor immunotherapy: CTLA4 blockade.
Gulley JL; Dahut WL
Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
[No Abstract] [Full Text] [Related]
6. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
[TBL] [Abstract][Full Text] [Related]
7. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Therapies in Prostate Cancer.
Goswami S; Aparicio A; Subudhi SK
Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
[TBL] [Abstract][Full Text] [Related]
9. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
Mai TJ; Ma R; Li Z; Bi SC
Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Graff JN; Li Z; Wu JD
Sci Adv; 2017 May; 3(5):e1602133. PubMed ID: 28560327
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
Elia AR; Caputo S; Bellone M
Front Immunol; 2018; 9():1786. PubMed ID: 30108594
[TBL] [Abstract][Full Text] [Related]
12. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
13. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
Bou-Dargham MJ; Sha L; Sang QA; Zhang J
BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self.
Miska J; Bas E; Devarajan P; Chen Z
Eur J Immunol; 2012 Oct; 42(10):2584-96. PubMed ID: 22777737
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: advances in immunotherapy.
Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED
BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491
[TBL] [Abstract][Full Text] [Related]
16. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for prostate cancer: recent developments and future challenges.
Schweizer MT; Drake CG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
19. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
[TBL] [Abstract][Full Text] [Related]
20. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
Thompson RH; Allison JP; Kwon ED
Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]